ReviewClinical medicine insights. Endocrinology and diabetes2015
Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review.
Review in Clinical medicine insights. Endocrinology and diabetes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.Diabetes care · 2025Pooled it
- Cost-effectiveness of Telephone-Delivered Education and Behavioral Skills Intervention for African American Adults with Diabetes.Ethnicity & disease · 2021Trial
- A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care.PharmacoEconomics - open · 2026Article
- Digital Health Interventions for Diabetes Distress in Type 2 Diabetes: Protocol for a Scoping Literature Review Focused on Equity and Inclusion.JMIR research protocols · 2026Article
- Impact of Pharmacist Educational Intervention on Costs of Medication with Improved Clinical Outcomes for Diabetic Patients in Various Tertiary Care Hospitals in Malaysia: A Randomized Controlled Trial.Healthcare (Basel, Switzerland) · 2025Article
- Diabetes diagnosis based on glucose control levels and time until diagnosis: a regression discontinuity approach to assess the effect on direct healthcare costs.Health economics review · 2025Article
- Type 2 Diabetes Mellitus andSouthern medical journal · 2024Article
- Disease and Economic Burden of Poor Metabolic and Weight Control in Type 2 Diabetes in Spain: A Systematic Literature Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Effect of physical activity counselling on the number of contacts in primary healthcare, specialised healthcare and the related healthcare costs among patients with type 2 diabetes: a register-based evaluation study.BMJ public health · 2023Article
- [The Economic Evaluation of the GLICEMIA 2.0 Study as an Example of a Complex Intervention].Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) · 2022Article
- Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
- Exploring HbA1c variation between Australian diabetes centres: The impact of centre-level and patient-level factors.PloS one · 2022Article
- Cost-Effectiveness of Technology-Assisted Case Management in Low-Income, Rural Adults with Type 2 Diabetes.Health equity · 2021Article
- Healthcare Costs of Diabetes and Microvascular and Macrovascular Disease in Individuals with Incident Type 2 Diabetes Mellitus: A Ten-Year Longitudinal Study.ClinicoEconomics and outcomes research : CEOR · 2020Article
- Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis.PLoS medicine · 2019Observational
- Costs of people with diabetes in relation to average glucose control: an empirical approach controlling for year of onset cohorts.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Observational
- Helicobacter pylori eradication improves glycemic control in type 2 diabetes patients with asymptomatic active Helicobacter pylori infection.Journal of diabetes investigation · 2019Article
- Pay for performance program reduces treatment needed diabetic retinopathy - a nationwide matched cohort study in Taiwan.BMC health services research · 2018Article
- Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis.PharmacoEconomics · 2018Article
- Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.Core evidence · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2D) is a growing healthcare burden primarily due to long-term complications. Strict glycemic control helps in preventing complications, and early introduction of insulin may be more cost-effective than maintaining patients on multiple oral agents. This is an expert opinion review based on English peer-reviewed articles (2000-2012) to discuss the health economic consequences of T2D treatment intensification. T2D costs are driven by inpatient care for treatment of diabetes complications (40%-60% of total cost), with drug therapy for glycemic control representing 18% of the total cost. Insulin therapy provides the most improved glycemic control and reduction of complications, although hypoglycemia and weight gain may occur. Early treatment intensification with insulin analogs in patients with poor glycemic control appears to be cost-effective and improves clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.